Nu Holdings Ltd vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Nu Holdings Ltd trades at $15.45 (market cap $75.26B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Nu Holdings Ltd is far larger — about 3× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| NU | RPRX | |
|---|---|---|
Market Cap | $75.26B | $25.27B |
Volume | 82,363,718 | 3,671,183 |
Sector | Financials | Health |
52-Week High | $18.76 | $63.96 |
52-Week Low | $11.60 | $35.44 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $97.88B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
NU Holdings trades at $15.38, down 1.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income reaching $2.9B. Recent news highlights market volatility around potential acquisition rumors, though the company has denied pursuing a Monzo deal.
The outlook remains positive with analyst consensus favoring Buy ratings (56.52%) and a $16.53 price target suggesting 7.5% upside. Key risks include credit quality concerns from expanding lending operations and high customer concentration. Revenue growth and profitability trends support continued investor interest despite recent earnings misses.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →